Get a Demo

16 min read

FDA, EMA, PMDA & More: Global Drug Approval Timelines Compared

Featured Image

Table of Contents

How do drug approval timelines actually compare across the FDA, EMA, PMDA, Health Canada, TGA, and Swissmedic? Each agency publishes its own target—EMA's standard procedure runs about 210 active days, FDA's goal is 10 months from a 60-day filing date—but a 2025 CIRS study of real 2015–2024 approvals found Japan's PMDA actually reviewed fastest in practice (a 290-day median), with Swissmedic slowest among the six (444 days). Official goals and real-world outcomes aren't the same thing.

Why Regulatory Review Timelines Vary So Much Across Agencies

Timelines differ because each agency measures its own review clock differently—what counts as a "day," when the clock starts, and whether it pauses—even though the underlying dossier each one reviews is nearly identical. Every major regulator reviewing a new active substance (NAS) application is, in theory, working from a shared foundation. The International Council for Harmonisation (ICH) has spent three decades aligning the technical content of submissions—common module structure, common data standards, a shared eCTD backbone—specifically so a dossier built for one agency doesn't have to be rebuilt from scratch for the next. And yet the clock each agency runs on that shared dossier looks nothing alike: the FDA measures its goal from a 60-day filing date, not the submission date; the EMA counts only "active days," pausing the clock entirely whenever the applicant is answering a question; Health Canada adds a fixed screening period before the review clock even starts; and Switzerland's Swissmedic reports both "total throughput time" (which includes company response time) and a separate, shorter "scientific assessment time" as two different numbers for the same review.

None of this is arbitrary. Clock-stop mechanics exist because every agency wants its own public "days to decision" number to reflect its own performance, not the time a sponsor spends drafting a response to a question. But it means a sponsor comparing six agencies' published goals side by side is, strictly speaking, comparing six different clocks—and that's before accounting for the practical reality that most companies don't file with every agency on the same day. A molecule's EMA timeline doesn't start until someone decides to submit to the EMA, and that decision is usually made well after the FDA filing, for reasons that have nothing to do with EMA's processing speed and everything to do with company sequencing strategy. Section What the Submission-Gap Data Actually Shows below digs into exactly how large that sequencing effect is.

This post works through each agency's own published goal timeline, then layers in independent real-world outcome data from a 2025 CIRS (Centre for Innovation in Regulatory Science) study[1] so you can see both the stated target and what reviews have actually taken in practice over the 2015–2024 period. For the US/EU pair specifically—including how the process differs for a first-in-human IND versus a CTA—see our companion piece, IND vs. CTA: Comparing US and EU Paths to First-in-Human Trials.

How We Compared These Six Agencies

We focused this comparison on the six jurisdictions most frequently benchmarked against each other in cross-agency regulatory planning—the FDA, EMA, PMDA, Health Canada, TGA, and Swissmedic—and used two layers of data for each:

  1. Official goal timelines. Each agency's own published performance standard or commitment letter: the FDA's PDUFA goals, the EMA's centralised-procedure timeline, Health Canada's performance standards, the TGA's registration-process targets, and Swissmedic's ordinary and expedited procedures. These are the numbers each agency is formally measuring itself against.
  2. Real-world outcome data. A 2025 CIRS study examining actual new active substance approvals across all six agencies between 2015 and 2024—reported by Regulatory Affairs Professionals Society (RAPS)[1]—plus Swissmedic's own 2026 follow-on release of CIRS's newer 2016–2025 data[2], which updates the EMA and Swissmedic figures specifically. We've kept these two CIRS datasets separate rather than blending them, since they cover different (overlapping but not identical) study windows.

A scoping note before we start: Kivo's own RIM eCTD Viewer actually supports eight regulatory jurisdictions, not six—it also accepts eCTD sequences for Singapore's Health Sciences Authority (HSA) and South Korea's Ministry of Food and Drug Safety (MFDS). We've scoped this specific comparison to the six agencies above because that's where the clearest apples-to-apples CIRS outcome data exists; see the Kivo RIM section below for where HSA and MFDS fit into the bigger picture.

At a Glance: Review Timelines Across Six Regulators

This table pairs each agency's own published goal with the CIRS study's real-world median approval time for 2015–2024[1]. "Goal timeline" reflects each agency's standard-pathway target as officially published; it is not directly comparable clock-for-clock (see the note on active vs. calendar days above), but it is the number each agency holds itself to.

AgencyStandard Goal TimelineExpedited/Priority OptionCIRS Median Approval Time (2015–2024)CIRS Median Submission Gap
FDA (US)10 months from 60-day filing date[3]6 months (priority review)[3]356 days0 days
EMA (EU)210 active days[4]150 active days (accelerated assessment)[5]430 days49 days
PMDA (Japan)12 months (standard, per sponsor/industry reporting)9 months (priority)290 days727 days
Health Canada300 days review + 45 days screening[6]180 days review + 25 days screening (priority)[6]363 days262 days
TGA (Australia)255 working days (Category 1)[7]150 working days (priority), per secondary reporting[8]369 days219 days
Swissmedic (Switzerland)Ordinary procedure (company + agency time)Expedited/fast-track procedures available444 days417 days

Two things jump out immediately. First, the agency with the shortest real-world median approval time (PMDA, at 290 days) also has by far the longest median submission gap (727 days)—sponsors overwhelmingly file in Japan last, often years after their first global filing, which gives PMDA a more mature, de-risked dossier to review. Second, Swissmedic's 444-day median and 417-day submission gap in the 2015–2024 dataset reflect an earlier period than Swissmedic's own 2026 release, which reports its 2025 total throughput time at 413 days against the EMA's 448—ranking second-fastest on scientific assessment time alone, at 303 days, behind only Japan[2]. We've called this out explicitly in each agency's own section below rather than averaging the two studies together.

Median Approval Time, 2015–2024 CIRS study of new active substance approvals across six agencies. Values in days, sorted shortest to longest: PMDA 290; FDA 356; Health Canada 363; TGA 369; EMA 430; Swissmedic 444. Median Approval Time, 2015–2024 CIRS study of new active substance approvals across six agencies PMDA 290 days FDA 356 days Health Canada 363 days TGA 369 days EMA 430 days Swissmedic 444 days
Median time from submission to approval for new active substances, 2015–2024, across all six agencies (CIRS study[1]).

FDA (United States)

Review Pathway & Goal Timelines

The FDA's review goals for New Molecular Entity (NME) NDAs and original BLAs are set through the Prescription Drug User Fee Act (PDUFA) commitment letters Congress reauthorizes roughly every five years. The current letter, covering PDUFA VIII (fiscal years 2028–2032), reaffirms the same structure that's governed FDA review goals since PDUFA V: act on 90% of standard NME NDA and original BLA submissions within 10 months of the 60-day filing date[3]. That 60-day filing date is itself a checkpoint, not a formality—FDA's review clock for the 10- or 6-month goal begins only after a 60-day filing review period that starts on the date FDA receives the original submission[3]. A major amendment submitted mid-review can extend the goal date by up to three months, and that extension can only be used once per review cycle[3].

Priority Review

Priority review shortens the same goal structure to 6 months from the 60-day filing date instead of 10, for 90% of qualifying submissions[3]. Eligibility turns on whether the drug, if approved, would provide a significant improvement in safety or effectiveness for a serious condition relative to available therapy—it's a clinical-benefit designation, not a queue-jump sponsors can request for any product.

Real-World Performance

The CIRS 2015–2024 study puts FDA's median approval time at 356 days[1]—longer than its own 10-month (roughly 300-day) standard goal including the 60-day filing period, which is a reasonable outcome for a median across both standard and priority submissions, rolling reviews, and amendment extensions. What stands out more is FDA's median submission gap: zero days[1]. At least half of the new active substances in the CIRS dataset were submitted to the FDA first, ahead of every other agency in this comparison.

What Sponsors Should Know

Filing the US first isn't a regulatory requirement anywhere in this comparison—it's a sponsor strategy choice, usually driven by US market size, US-centric trial populations, and the practical reality that FDA interactions (End-of-Phase 2 meetings, Breakthrough Therapy designation) often shape the dossier that eventually goes to other agencies too. Teams managing a US-first sequencing strategy need their regulatory information management system to track not just the FDA submission itself, but the downstream plan for when each other agency's package goes out and how it needs to be adapted.

EMA (European Union)

Review Pathway & Goal Timelines

The EMA's centralised procedure runs on a 210 active-day scientific assessment clock, officially described in EMA's own step-by-step guidance to obtaining an EU marketing authorisation[4]. "Active days" is the operative concept: EMA defines a "clock stop" as a period during which evaluation is officially paused while the applicant prepares responses to the regulatory authority's questions, resuming only once those responses are sent back[9]. Those clock-stop periods don't count against the 210-day figure, which is why the calendar-time gap between submission and authorisation in the EU is routinely longer than 210 days in practice. Once the CHMP (Committee for Medicinal Products for Human Use) issues its scientific opinion, the European Commission takes that opinion and issues the legally binding marketing authorisation within 67 days of receiving it[4]—a separate, additional step beyond the CHMP's own 210-day clock.

Accelerated Assessment

For products of major public health interest, particularly regarding therapeutic innovation, the CHMP can reduce the scientific-assessment timeframe to 150 active days, split roughly into 90 days of initial assessment plus two further 30-day assessment rounds[5]. Requesting accelerated assessment requires justification and, in practice, a dossier that's essentially complete and ready to withstand compressed review at submission—it isn't a designation that compensates for a weaker or less mature package.

Real-World Performance

The CIRS 2015–2024 study reports EMA's median approval time at 430 days, with a median submission gap of 49 days—the second-shortest gap after FDA's zero[1]. Swissmedic's 2026 release of CIRS's newer 2016–2025 figures puts EMA's total throughput time at 448 days for 2025 specifically, against Swissmedic's own 413[2]—consistent directionally with the earlier study, even though the two datasets cover different (though overlapping) years and shouldn't be averaged together.

What Sponsors Should Know

Because EMA's submission timing tends to follow FDA's relatively closely (a 49-day median gap is measured in weeks, not years), EU regulatory teams are often working the dossier in parallel with the US filing rather than waiting for a US decision first. That makes document-version control and EU-specific regional module tracking (Module 1 content, EU-specific labelling and IMPD-style content for the clinical phase) a live, concurrent workstream rather than a sequential one. For the document-management side of CTIS compliance specifically, see CTIS Part II: Document Management Best Practices for CTR Compliance, and for the EU marketing-authorisation application itself, see our Marketing Authorisation Application (MAA) Submission Guide.

PMDA (Japan)

Review Pathway & Goal Timelines

Japan's Pharmaceuticals and Medical Devices Agency targets roughly 12 months for a standard new drug review, a figure widely reported by sponsors and regulatory-affairs professionals navigating the Japanese approval process, with a reduced target of roughly 9 months available for priority-designated products. Unlike the FDA's and EMA's published commitment-letter-style goals, PMDA's published standards are less uniformly codified in a single public goals document in the way PDUFA or the EU regulation are—sponsors and consultancies most often cite these figures from PMDA's own review-performance reporting and industry guidance rather than a single commitment letter.

Priority Review

Priority consultation and review in Japan is generally reserved for products addressing serious diseases with high unmet medical need, similar in spirit to FDA's priority-review standard, though the designation process and criteria are specific to Japan's own Pharmaceuticals, Medical Devices and Other Therapeutic Products Act framework.

Real-World Performance

This is where PMDA stands out most clearly in the data: the CIRS 2015–2024 study found PMDA had the shortest median approval time of all six agencies, at 290 days[1]—faster than every Western regulator in this comparison, including FDA's 356 and EMA's 430. But PMDA also had by far the longest median submission gap, at 727 days[1]—roughly two years after the typical first global filing. Those two facts are connected, not contradictory: a dossier that reaches PMDA two years after its first global submission has usually already absorbed feedback, amendments, and real-world data from earlier reviews elsewhere, which materially shortens what PMDA itself needs to evaluate.

What Sponsors Should Know

PMDA's fast median review time is not, on its own, evidence that Japan is an "easy" or low-friction market to file in first—the data suggests the opposite: sponsors who file in Japan early, without the benefit of a settled global dossier, should not assume PMDA's 290-day median applies to them. Teams planning a Japan filing as part of a broader global sequencing strategy need visibility into exactly which dossier version, amendments, and supporting data package is going to PMDA relative to what's already gone to other agencies.

Health Canada

Review Pathway & Goal Timelines

Health Canada's performance standards for a standard New Drug Submission (NDS) containing a new active substance set a 300-calendar-day Review 1 target, preceded by a 45-calendar-day Screening 1 period before substantive review begins[6]—roughly 345 days screening-to-decision when both phases are added together. A separate 10-calendar-day administrative processing step precedes screening itself. If Health Canada doesn't meet its own published performance standard on a given submission, its cost-recovery framework credits sponsors 25% of the original review fee—a real financial consequence tied to the published standard, not just a public-reporting metric.

Priority Review

Health Canada's priority review track compresses Review 1 to 180 calendar days with a 25-day Screening 1[6], available for a New Drug Submission or Supplemental New Drug Submission addressing a serious, life-threatening, or severely debilitating disease where substantial evidence shows either an effective treatment for a disease with no currently marketed drug in Canada, or a significant increase in efficacy or decrease in risk relative to existing therapies[10]. Sponsors typically submit a written request and Clinical Assessment Package ahead of the full filing; Health Canada aims to respond to that request within 30 calendar days, and the full submission then follows within 60 calendar days of acceptance[10].

Real-World Performance

The CIRS 2015–2024 study places Health Canada's median approval time at 363 days—close to, but somewhat above, its own roughly 345-day combined standard target—with a median submission gap of 262 days[1], putting Canada in the middle of this group: sponsors typically file there well after the US and EU, but well before Japan.

What Sponsors Should Know

Health Canada's two-phase structure (a distinct, time-bound screening step ahead of substantive review) means an incomplete or poorly organized initial filing carries a specific, quantifiable cost: a screening failure doesn't just delay review, it can restart a clock that's already built into the agency's own performance-standard math. Keeping the administrative completeness of a Canadian filing package airtight before submission matters more here than in agencies without a formally separated screening phase.

TGA (Australia)

Review Pathway & Goal Timelines

Australia's Therapeutic Goods Administration targets 255 working days for a Category 1 (standard, full clinical evaluation) prescription-medicine registration, a figure TGA itself has reported meeting on 94–100% of applications in recent public performance reporting[7]. TGA's registration dossiers follow the ICH Common Technical Document (CTD) format, with TGA-specific regional requirements layered on top, and the agency has been transitioning categories of applications to mandatory eCTD submission in staged phases[7].

Category 2, Category 3, and Priority Review

Beyond Category 1, TGA's registration framework includes abridged and verification pathways with shorter targets—regulatory consultancies reviewing TGA's published guidance commonly cite roughly 175 working days for Category 3 (verification) applications and roughly 150 working days under Priority Review designation[8]. We're flagging these two figures specifically as drawn from secondary regulatory-consultancy reporting rather than a single current TGA primary-source document we were able to independently verify line-by-line—treat them as directionally accurate but worth confirming against TGA's own current fees-and-timeframes guidance before using them in a submission plan.

Real-World Performance

The CIRS 2015–2024 study reports TGA's median approval time at 369 days, with a median submission gap of 219 days[1]—the shortest gap among the non-FDA/EMA agencies in this comparison, suggesting Australian filings tend to follow relatively close behind the US and EU rather than waiting for a fully mature global dossier.

What Sponsors Should Know

TGA's CTD-aligned, ICH-consistent dossier format means a well-built eCTD package prepared for FDA or EMA submission translates relatively cleanly to a TGA filing with Australia-specific regional content layered in—this is one of the more straightforward "fourth or fifth" filings in a global sequencing plan precisely because the underlying dossier structure doesn't need to be substantially rebuilt.

Swissmedic (Switzerland)

Review Pathway & Goal Timelines

Swissmedic reports its own performance using two distinct figures for the same review: a "scientific assessment time" (core agency evaluation plus company time spent responding to questions) and a longer "total throughput time" that also includes formal review steps and labelling finalization after a preliminary approval decision[2]. In its most recent published comparison, covering 2025 data from a CIRS study, Swissmedic's total throughput time was 413 days, faster than the EMA's 448 days for the same period[2].

Expedited Procedures

Swissmedic offers expedited and fast-track authorisation procedures for medicines addressing serious or life-threatening conditions with no satisfactory existing treatment, broadly analogous in purpose to FDA's priority review and EMA's accelerated assessment, though governed by Switzerland's own Therapeutic Products Act framework rather than PDUFA or EU regulation.

Real-World Performance

On scientific assessment time alone—stripping out the additional formal-review and labelling steps—Swissmedic ranked second-fastest among the agencies covered in the 2025 CIRS data, at 303 days, trailing only Japan's PMDA[2]. That's a meaningfully different picture than the earlier 2015–2024 CIRS dataset, where Swissmedic's median approval time of 444 days and submission gap of 417 days placed it at the slower end of this six-agency comparison[1]—a reminder that these are two different (if overlapping) study windows, and Swissmedic's more recent standalone data shows a materially faster scientific-assessment figure than the older blended dataset suggests on its own.

What Sponsors Should Know

Switzerland's position outside the EU means a Swissmedic filing is a genuinely separate regulatory submission, not a byproduct of an EMA filing—sponsors need a standalone Swiss dossier and a standalone Swiss timeline in their planning, even when the underlying clinical package is otherwise aligned with the EU submission.

What the Submission-Gap Data Actually Shows

Lay the CIRS 2015–2024 figures[1] for median approval time next to median submission gap, agency by agency, and a pattern emerges that's easy to miss if you only look at one column at a time: the agencies with the shortest median approval times (PMDA at 290 days, FDA at 356) sit at opposite ends of the submission-gap spectrum (727 days versus 0 days), and the agencies with the longest approval times (Swissmedic at 444, EMA at 430) also don't cluster neatly by submission gap either (417 days versus 49 days). Approval speed, in other words, isn't simply "fast agency" versus "slow agency"—it's substantially a function of how mature the dossier already is by the time a given agency sees it, which is itself a function of a sponsor's own filing-sequence decisions.

The practical implication for a global regulatory team: the single biggest lever you control over how fast any individual agency's review actually goes isn't which agency you're dealing with—it's how much global review feedback has already been absorbed into the dossier before that agency receives it. A submission strategy built around "file everywhere as fast as possible" and a submission strategy built around "file sequentially and let each review mature the next dossier" will produce very different real-world timelines from the same six agencies, even though neither strategy changes a single one of the official goal numbers in the comparison table above.

Median Submission Gap, 2015–2024 Days after a sponsor's first global filing that each agency typically received the same submission. Values in days, sorted shortest to longest: FDA 0; EMA 49; TGA 219; Health Canada 262; Swissmedic 417; PMDA 727. Median Submission Gap, 2015–2024 Days after a sponsor's first global filing that each agency typically received the same submission FDA 0 days EMA 49 days TGA 219 days Health Canada 262 days Swissmedic 417 days PMDA 727 days
Median number of days after a sponsor's first global filing that each agency typically received the same submission, 2015–2024 (CIRS study[1]).

How Kivo's RIM Module Keeps Multi-Jurisdiction Submissions on Track

Running six (or eight) simultaneous or sequential regulatory timelines against one evolving dossier is, structurally, a document-version-control and correspondence-tracking problem as much as it's a regulatory-strategy problem. Kivo's Regulatory Information Management (RIM) module is built around exactly that reality: it manages the regulatory submission lifecycle, agency correspondence, and commitment tracking for sponsors filing INDs, CTAs, BLAs, NDAs, IDMPs, ANDAs, and CTIS submissions, built on the EDM (Electronic Document Management) Reference Model.

The module's eCTD Viewer is where the multi-jurisdiction picture comes together directly: it accepts eCTD sequences for all eight jurisdictions where eCTD is in use today—the FDA, EMA, PMDA, Health Canada, Swissmedic, and TGA covered in this comparison, plus Singapore's Health Sciences Authority (HSA) and South Korea's Ministry of Food and Drug Safety (MFDS)—supporting eCTD 4.0, sequence and cumulative views, module-level navigation, inline study tagging, and submission archiving, all browser-based with no local install required. Kivo doesn't handle eCTD publishing itself; instead it prepares submission-ready packages with automatic change tracking for handoff to a sponsor's own internal or external publishing group, and keeps every submitted sequence viewable afterward, linked back to its source documents in Kivo's DMS.

Correspondence and commitment tracking—capturing agency emails, digital files, call logs, PDFs, and scanned documents, with smart associations and automated reporting by agency, project, or request type—is one of the capabilities regulatory teams call out most often when comparing Kivo to larger, more rigid enterprise RIM systems; for a direct look at how that compares to one widely-used enterprise alternative, see Kivo vs. Veeva Vault RIM: A Side-by-Side Comparison, and for a broader look at what a modern RIM system needs to do well, see The Features That Define a Modern RIM System. Over 200 sponsor, consultant, and CRO teams currently run on Kivo's platform, managing more than 250 regulatory applications[11], and because DMS, RIM, eTMF, and QMS all share the same document core, permissioning model, audit trail, and native Part 11-compliant e-signature—included standard, with no additional charge—regulatory teams don't need a separate integration project to connect submission tracking to the rest of their compliance stack.

FAQ

Which regulatory agency has the fastest drug approval timeline?

Based on CIRS's 2015–2024 study, Japan's PMDA had the shortest median approval time among these six agencies, at 290 days[1]. But PMDA also had the longest median submission gap (727 days)—sponsors typically file there only after a dossier has matured through earlier reviews elsewhere, so that speed may not hold for a first-ever global filing.

Why do official regulatory timelines differ so much from real-world approval times?

Official goals like the FDA's 10-month PDUFA standard or the EMA's 210 active days measure only the agency's formal review clock, which pauses during "clock stops" while sponsors prepare responses. Real-world totals, like the CIRS study's figures, capture the full calendar time including those pauses—so they're almost always longer than the published goal.

Does filing with the FDA first mean other agencies will review faster?

Not automatically, but the data suggests a correlation: agencies that receive a submission later in a company's global filing sequence (like PMDA, at a 727-day median gap) tend to review a more mature, already-vetted dossier, which can shorten their own review time even though it has nothing to do with that agency's inherent speed.

What's the difference between Swissmedic's "scientific assessment time" and "total throughput time"?

Scientific assessment time covers Swissmedic's core evaluation plus the time a company spends responding to questions. Total throughput time adds the formal review steps and labelling finalization that follow a preliminary approval decision—so it's always the larger of the two numbers for the same submission[2].

Does the EU's Clinical Trials Regulation (CTR/CTIS) change the marketing-authorisation timelines covered here?

No—CTIS and the Clinical Trials Regulation govern the clinical-trial application process, not the centralised marketing-authorisation procedure covered in this comparison. The 210 active-day and accelerated-assessment timelines here apply once a sponsor files for marketing authorisation, after clinical trials are complete.

Sources

  1. Al-Faruque, Ferdous. "Report: Japan's PMDA had shortest review times for new drugs, half of drugs submitted to US first." Regulatory Affairs Professionals Society (RAPS), 20 August 2025, reporting on CIRS R&D Briefing 101 (2015–2024 data).
  2. Swissmedic. "CIRS study on authorisation times for human medicinal products with new active substances confirms Swissmedic's competitiveness internationally." 6 July 2026, reporting on CIRS R&D Briefing 106 (2016–2025 data).
  3. U.S. Food and Drug Administration. "PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2028 Through 2032" (PDUFA VIII commitment letter).
  4. European Medicines Agency. "Obtaining an EU marketing authorisation, step-by-step."
  5. EUPATI Open Classroom. "Accelerated assessment" course page, citing Article 14(9) of Regulation (EC) No 726/2004.
  6. Health Canada. "Guidance Document: Management of Drug Submissions and Applications – Performance standards." Modified 1 October 2025.
  7. Therapeutic Goods Administration. "Updates from the Prescription Medicine Authorisation Branch," ARCS Annual Conference presentation, 24 May 2022.
  8. DDRegpharma. "TGA Australia Drug Registration: Your Fast-Track Guide to Therapeutic Goods Act Compliance" (secondary/consultancy source for Category 2/3 and Priority Review figures).
  9. European Medicines Agency. Glossary: "Clock stop."
  10. Health Canada. "Priority Review of Drug Submissions" guidance document. Modified 2 December 2024.
  11. Kivo. "About" page, company and platform statistics.

IND vs. CTA: Comparing US and EU Paths to First-in-Human Trials

What is the difference between an IND application in the US and a CTA in the EU for a first-in-human clinical trial?

An Investigational New Drug (IND) application is filed with the U.S. FDA...

17 November 2026
17 min read

Clinical Document Management for Multi-Country Trials

Clinical document management for multi-country study teams means giving every site, country lead, and central function controlled, auditable access to the same trial documents — without...

9 November 2026
6 min read

IND vs. CTA: Comparing US and EU Paths to First-in-Human Trials

What is the difference between an IND application in the US and a CTA in the EU for a first-in-human clinical trial?

An Investigational New Drug (IND) application is filed with the U.S. FDA...

17 November 2026
17 min read

Clinical Document Management for Multi-Country Trials

Clinical document management for multi-country study teams means giving every site, country lead, and central function controlled, auditable access to the same trial documents — without...

9 November 2026
6 min read